Novel variants and haplotypes of human flavin-containing monooxygenase 3 gene associated with Japanese subjects suffering from trimethylaminuria

References

• Akerman BR, Lemass H, Chow LM, et al. (1999). Trimethylaminuria is caused by mutations of the FMO3 gene in a North American cohort. Mol Genet Metab 68:24–31.
   PubMed Web of Science ®Google Scholar
• Allerston CK, Shimizu M, Fujieda M, et al. (2007). Molecular evolution and balancing selection in the flavin-containing monooxygenase 3 gene (FMO3). Pharmacogenet Genomics 17:827–39.
   PubMed Web of Science ®Google Scholar
• Allerston CK, Vetti HH, Houge G, et al. (2009). A novel mutation in the flavin-containing monooxygenase 3 gene (FMO3) of a Norwegian family causes trimethylaminuria. Mol Genet Genomics 98:198–202.
   Google Scholar
• Amoore JE, Gumbmann MR, Booth AN, Gould DH. (1978). Synthetic flavors: efficiency and safety factors for sweaty and fishy odorants. Chem Sense Flavour 3:307–17.
   Web of Science ®Google Scholar
• Bain MA, Milne RW, Evans AM. (2006). Disposition and metabolite kinetics of oral l-carnitine in humans. J Clin Pharmacol 46:1163–70.
   PubMed Web of Science ®Google Scholar
• Bennett BJ, de Aguiar Vallim TQ, Wang Z, et al. (2013). Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab 17:49–60.
   PubMed Web of Science ®Google Scholar
• Collins HL, Drazul-Schrader D, Sulpizio AC, et al. (2016). l-Carnitine intake and high trimethylamine N-oxide plasma levels correlate with low aortic lesions in ApoE(-/-) transgenic mice expressing CETP. Atherosclerosis 244:29–37.
   PubMed Web of Science ®Google Scholar
• Fennema D, Phillips IR, Shephard EA. (2016). Trimethylamine and trimethylamine N-oxide, a flavin-containing monooxygenase 3 (FMO3)-mediated host-microbiome metabolic axis implicated in health and disease. Drug Metab Dispos 44:1839–50.
   PubMed Web of Science ®Google Scholar
• Furnes B, Feng J, Sommer SS, Schlenk D. (2003). Identification of novel variants of the flavin-containing monooxygenase gene family in African Americans. Drug Metab Dispos 31:187–93.
   PubMed Web of Science ®Google Scholar
• Hernandez D, Addou S, Lee D, et al. (2003). Trimethylaminuria and a human FMO3 mutation database. Hum Mutat 22:209–13.
   PubMed Web of Science ®Google Scholar
• Krueger SK, Williams DE. (2005). Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther 106:357–87.
   PubMed Web of Science ®Google Scholar
• Kubota M, Nakamoto Y, Nakayama K, et al. (2002). A mutation in the flavin-containing monooxygenase 3 gene and its effects on catalytic activity for N-oxidation of trimethylamine in vitro. Drug Metab Pharmacokinet 17:207–13.
   PubMedGoogle Scholar
• Lambert DM, Mamer OA, Akerman BR, et al. (2001). In vivo variability of TMA oxidation is partially mediated by polymorphisms of the FMO3 gene. Mol Genet Metab 73:224–9.
   PubMed Web of Science ®Google Scholar
• Mitchell SC, Smith RL. (2001). Trimethylaminuria: the fish malodor syndrome. Drug Metab Dispos 29:517–21.
   PubMed Web of Science ®Google Scholar
• Motika MS, Zhang J, Zheng X, et al. (2009). Novel variants of the human flavin-containing monooxygenase 3 (FMO3) gene associated with trimethylaminuria. Mol Genet Metab 97:128–35.
   PubMed Web of Science ®Google Scholar
• Nagashima S, Shimizu M, Yano H, et al. (2009). Inter-individual variation in flavin-containing monooxygenase 3 in livers from Japanese: correlation with hepatic transcription factors. Drug Metab Pharmacokinet 24:218–25.
   PubMed Web of Science ®Google Scholar
• Phillips IR, Shephard EA. (2017). Drug metabolism by flavin-containing monooxygenases of human and mouse. Expert Opin Drug Metab Toxicol 13:167–81.
   PubMed Web of Science ®Google Scholar
• Shephard EA, Treacy EP, Phillips IR. (2012). Clinical utility gene card for: trimethylaminuria. Eur J Hum Genet 20:e1–5.
   PubMed Web of Science ®Google Scholar
• Shephard EA, Treacy EP, Phillips IR. (2015). Clinical utility gene card for: trimethylaminuria – update 2014. Eur J Hum Genet 23.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Allerston CK, Shephard EA, et al. (2014). Relationships between flavin-containing monooxygenase 3 (FMO3) genotype and trimethylaminuria phenotype in a Japanese population. Br J Clin Pharmacol 77:839–51.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Denton T, Kozono M, et al. (2011). Developmental variations in metabolic capacity of flavin-containing mono-oxygenase 3 in childhood. Br J Clin Pharmacol 71:585–91.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Fujita H, Aoyama T, Yamazaki H. (2006). Three novel single nucleotide polymorphisms of the FMO3 gene in a Japanese population. Drug Metab Pharmacokinet 21:245–7.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Kobayashi Y, Hayashi S, et al. (2012). Variants in the flavin-containing monooxygenase 3 (FMO3) gene responsible for trimethylaminuria in a Japanese population. Mol Genet Metab 107:330–4.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Origuchi Y, Ikuma M, et al. (2015). Analysis of six novel flavin-containing monooxygenase 3 (FMO3) gene variants found in a Japanese population suffering from trimethylaminuria. Mol Genet Metab Rep 5:89–93.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Shiraishi A, Sato A, et al. (2015). Potential for drug interactions mediated by polymorphic flavin-containing monooxygenase 3 in human livers. Drug Metab Pharmacokinet 30:70–4.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Tomioka S, Murayama N, Yamazaki H. (2007). Missense and nonsense mutations of the flavin-containing monooxygenase 3 gene in a Japanese cohort. Drug Metab Pharmacokinet 22:61–4.
   PubMed Web of Science ®Google Scholar
• Teresa E, Lonardo F, Fiumara A, et al. (2006). A spectrum of molecular variation in a cohort of Italian families with trimethylaminuria: identification of three novel mutations of the FMO3 gene. Mol Genet Metab 88:192–5.
   PubMed Web of Science ®Google Scholar
• Wagmann L, Meyer MR, Maurer HH. (2016). What is the contribution of human FMO3 in the N-oxygenation of selected therapeutic drugs and drugs of abuse? Toxicol Lett 258:55–70.
   PubMed Web of Science ®Google Scholar
• WHO. (2006). Food additives series: 56, safety evaluation of certain food additives, aliphatic and aromatic amines and amides (report of 65th JECFA meeting). World Health Organization, Geneva, Switzerland.
   Google Scholar
• Yamazaki H, Fujieda M, Togashi M, et al. (2004). Effects of the dietary supplements, activated charcoal and copper chlorophyllin, on urinary excretion of trimethylamine in Japanese trimethylaminuria patients. Life Sci 74:2739–47.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Fujita H, Gunji T, et al. (2007). Stop codon mutations in the flavin-containing monooxygenase 3 (FMO3) gene responsible for trimethylaminuria in a Japanese population. Mol Genet Metab 90:58–63.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Shimizu M. (2007). Genetic polymorphism of the flavin-containing monooxygenase 3 (FMO3) associated with trimethylaminuria (fish odor syndrome): observations from Japanese patients. Curr Drug Metab 8:487–91.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Shimizu M. (2013). Survey of variants of human flavin-containing monooxygenase 3 (FMO3) and their drug oxidation activities. Biochem Pharmacol 85:1588–93.
   PubMed Web of Science ®Google Scholar